Calcium-channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients.
Deniz TürkmenJane A H MasoliJoão DelgadoChia-Ling KuoJack BowdenDavid MelzerLuke C PillingPublished in: British journal of clinical pharmacology (2022)
Patients with common genetic variants in NUMA1, CYP3A5 and RYR3 had increased adverse clinical outcomes. Work is needed to establish whether outcomes of dCCB prescribing could be improved by prior knowledge of pharmacogenetics variants supported by clinical evidence of association with adverse events.
Keyphrases
- end stage renal disease
- newly diagnosed
- copy number
- ejection fraction
- primary care
- healthcare
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- type diabetes
- emergency department
- adverse drug
- patient reported outcomes
- gene expression
- angiotensin converting enzyme
- metabolic syndrome
- genome wide
- patient reported
- glycemic control